CONCLUSIONS AND RELEVANCE In this large survey study, OPC survivors with late LCNP reported worse cancer treatment-related symptoms, a finding suggesting an association between late LCNP and symptom burden. This research may inform the development and implementation of strategies for LCNP surveillance and management.
T he incidence of oropharyngeal cancer (OPC) is increasing by 5% annually in the United States. 1 It is projected that, by 2030, half of head and neck cancers (HNCs) will be OPC. 1 This projection is attributable to the epidemic of human papillomavirus-associated OPC, which is usually diagnosed in middle age. [1] [2] [3] [4] Human papillomavirus disease is biologically favorable, with excellent prognosis for long-term survival despite advanced-stage cancer. [2] [3] [4] Despite excellent prognosis, survivors may experience severe adverse consequences of cancer treatment, such as speech, breathing, and swallowing difficulties. Late lower cranial neuropathies (LCNPs) are a rare but potentially severe late consequence of damage caused by radiotherapy (RT) and other cancer therapies. Lower cranial nerves include glossopharyngeal (cranial nerve IX), vagus (cranial nerve X), accessory (cranial nerve XI), and hypoglossal (cranial nerve XII) nerves, which are critical to the oropharyngeal phases of swallowing, shoulder function, and speech, respectively. [5] [6] [7] [8] [9] Fibrosis of nerve tracts or adjacent soft tissues can lead to delayed, typically progressive, neurovascular damage and eventually neuropathy, which over time causes profound functional impairments. 5 According to a recent single institution report, 6 the incidence of delayed LCNP among 59
OPC survivors was 5% at 5.7 years. Although late LCNP is rare, case reports suggest profound functional impairments and overall low quality of life (QOL) among patients with LCNP. [5] [6] [7] [8] Symptom burden is defined as severity of symptoms experienced by patients and the bearing of those symptoms on day-to-day life. 10 Patients may experience symptoms attributable to disease, recurrence, or treatment-related toxic effects. 10 Late toxic effects, such as late LCNP, conventionally persist or occur 3 months or later after treatment completion but may develop even years later.
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General functional impairment (GFI) is defined as a diminished ability to take care of oneself, manage the household, work, and indulge in activities for relaxation. 12 Thus, GFI can impede the daily lives of survivors. 12 Treatment-related symptoms may have a detrimental bearing on GFI marked by symptom interference scores. For some patients, the impairment is temporary, and with time, these patients return to normal activity and function. However, a substantial number of OPC survivors continue to experience limitations and disability and may be unable to return to normal activities, including work, leading to a long-term economic consequence. 12, 13 Previous studies 7, 8 on late RT-associated LCNP have been case reports or small case series or included cohorts of predominantly nasopharyngeal cancer survivors. In OPC, severe symptoms have been described among patients with LCNP, but the association between late LCNP and symptoms, as well as GFI, has yet to be quantified. For the increasing numbers of OPC survivors at risk for experiencing LCNP, it is critical to quantify the association between late LCNP and severity of cancer treatment-related symptoms and GFI to inform development and implementation of targeted strategies for late effect surveillance and management. The purpose of this analysis was to investigate the severity of cancer treatment-related symptoms (per the primary end point of the mean top 5 MD Anderson Symptom Inventory Head and Neck Cancer Module [MDASI-HN] symptom scores) and their subsequent association with GFI (per the secondary end point of mean MDASI-HN interference score) by late LCNP status among OPC survivors. The association of late LCNP and overall mean symptom burden of single-item scores among the most severe symptoms and categorical ratings of the top 5 symptoms was also assessed to explore the association with diverse symptom metrics. We hypothesized that late LCNP status would be associated with worse symptom scores and GFI.
Methods

Patient Eligibility
A cross-sectional, patient-reported outcome survey was conducted among survivors of a retrospective cohort of patients with OPC treated at MD Anderson Cancer Center from January 1, 2000, to December 31, 2013. Eligible participants were 18 years or older at diagnosis, completed OPC treatment 1 year or more before survey administration, and consented to future research participation at new patient registration within the institution. Deceased patients, those who had a secondary primary malignant tumor or recurrent malignant tumor of the head and neck before survey, and those whose primary language was not English were excluded. Patients with LCNP of any cause at the time of cancer diagnosis or with clinical signs of LCNP before starting cancer treatment were also excluded. Figure 1 shows participant recruitment and eligibility criteria for the study. Data analysis was performed from October 10, 2017, to March 15, 2018. Details of survey administration and response have been published previously.
14 The MD Anderson Cancer Center institutional review board approved this study with use of a consent statement on the survey cover letter for informed consent of survey responders.
OPC Treatment
Institutional practices regarding OPC treatment during the period of this study have been previously described. 15 For treatment of primary tumors and nodes in the upper neck region, the IMRT approach was predominantly used, whereas for nodes in the lower neck anterior beam, a technique with laryngeal and/or full midline block was used. Furthermore, for treatment of primary tumors and the neck region when split-field IMRT was not possible, the whole-field IMRT technique was used. Individual extent of primary disease and preexisting comorbidities were taken into account to decide whether patients would receive systemic therapy. Definitive surgery with transoral resection to the primary site was rare, but after 2009, a small number of patients were treated with transoral robotic surgery with adjuvant therapy based on pathologic features.
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Demographic and Clinical Variables
Age at diagnosis, sex, race/ethnicity, educational level, smoking history, and human papillomavirus and p16 status were abstracted from electronic medical records. Clinical and treatment data abstracted included subsite of primary OPC tumor, tumor and nodal stage (American Joint Committee on Cancer version VII), treatment modality, RT dose, modality and fractionation, surgery, chemotherapeutic regimen, and ability to eat solid food at baseline (surrogate for baseline dysphagia).
Survival time was calculated as the difference between age at diagnosis and age at time of survey administration.
Survey Items
The MDASI-HN is a 28-item, validated, patient-reported outcome instrument that evaluates symptom severity and interference in patients with HNC. The MDASI-HN includes 13 questions to assess core symptoms common across all cancers and 9 questions to assess HNC-specific symptoms. The MDASI-HN symptom severity item scores range from 0, indicating not present, to 10, indicating as bad as you can imagine. The MDASI-HN also includes 6 interference questions to assess the bearing of symptoms on daily function with respect to general activity, walking, work, mood, relationships with other people, and enjoyment of life. These item scores range from 0, indicating do not interfere, to 10, indicating interfere completely, such that higher scores indicate more limitations and lower QOL. [14] [15] [16] [17] [18] [19] [20] [21] Symptom and interference scores are commonly classified as follows: 0, no symptom; 1 to 3, mild; 4 to 6, moderate; and 7 to 10, severe symptoms. 22 Mean subscale scores are internally consistent (Cronbach α = 0.72-0.92).
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Primary Exposure
Late LCNP was assessed during surveillance and rehabilitation visits by clinical examination of cranial nerves by head and neck surgeons, radiation oncologists, and speech pathologists and recorded in medical records. Late LCNP was defined as onset of swallowing-associated neuropathy of at least 1 of the glossopharyngeal (cranial nerve IX), vagus (cranial nerve X), and hypoglossal (cranial nerve XII) nerves, with minimum onset 3 months or more after the end of cancer treatment. Three months is considered the start of the late toxic effect interval according to the National Cancer Institute's Common Toxicity Criteria Manual: "Late radiation effects are defined as effects that occur 90 days and onwards after initiation of RT treatment." 11(p24) For this reason, we elected to code any onset of LNCP after 3 months and up until the survey response as a late LCNP. Polyneuropathy was present in some patients with LCNP, but there was no standard method to document degree of neuropathy in medical records. Medical records were reviewed to identify LCNP cases. Physical examination reports were reviewed in detail. Objective methods, such as endoscopy and radiographic swallow studies, were not universally available for such a large study sample but were reviewed in detail when available. Computed tomography and magnetic resonance imaging were used to verify LCNP, but they were not a requirement for case status assessment. Case status was verified through independent review by a head and neck surgeon (R.P.G.) with review of surveillance computed tomography and magnetic resonance imaging to rule out malignant tumors or other sources of neuropathy. Electromyography was not routinely used.
Primary Outcome
The primary outcome variable for this study was the mean of the top 5 most severely scored symptoms of all 22 core and HNC-specific symptoms. This method, reported in the MDASI as an estimate of the severity of the most meaningful and prevalent symptoms reported by this population.
Secondary Outcome
Results of the MDASI-HN can be summarized in various ways. Therefore, 4 secondary outcomes of the MDASI-HN were evaluated to fully explore the association of late LCNP with symptom burden. Secondary outcomes included (1) overall mean of 22 symptom items, (2) mean interference, (3) single-item scores of the top 5 most severe symptoms, and (4) categorical ratings of the top 5 symptoms.
Overall mean symptom scores summarize all 22 items of core and HNC-specific symptoms to reflect overall symptom severity. Mean interference serves as a marker of GFI with subdomains of activity-related interference (using item scores related to general activity, work, and walking) and psychosocialrelated interference (using item scores related to mood, relationships with other people, and enjoyment of life). Singleitem scores of the top 5 most severe symptoms, although extant in our primary end point (mean of the top 5 symptoms), were evaluated separately to reflect the association of LCNP with individual symptoms. Single-item scores were considered to provide insight on particular functional domains with the greatest negative association with LCNP, which might help to focus supportive care efforts for this population. Finally, categorical ratings were examined to allow ease of clinical interpretation to identify proportions of patients with LCNP experiencing high-grade symptoms.
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Statistical Analysis
Descriptive and univariate analyses were performed. For the primary outcome (mean top 5 MDASI-HN symptom scores), multiple linear regression was used to investigate associations between LCNP status and MDASI-HN scores, controlling for age, sex, race/ethnicity, T stage, subsite, RT dose, fractionation and modality, chemotherapy, surgery, eating solid food at baseline, survival time, and smoking, which according to previous literature are cofactors associated with toxic effects and symptom burden. 27, 28 Model building followed the purposeful variable selection method of Hosmer and Lemeshow. 29 Candidate predictive factors with P < .25 on the univariate Wald test were entered into multivariable models and removed stepwise (P > .20). Age, T stage, subsite, treatment modality, and smoking were a priori retained as clinically important covariates and included in all models. Coefficients (unadjusted and adjusted) and corresponding 95% CIs were estimated. The association of late LCNP and secondary outcomes was evaluated using multiple regression methods adjusting for the same variables as the primary outcome analysis. All data were analyzed without imputation for missing information. Given our consideration of multiple MDASI-HN scores as symptom burden outcomes, analysis of all 12 primary and secondary outcomes, including mean top 5 symptom scores, overall 22-item mean score, mean interference (including activityrelated and psychosocial domains) score, individual scores for the top 5 symptoms, and voice and categorical ratings, was corrected for multiple comparisons. After Bonferroni correction (α = 0.05/12), statistical significance was conferred at P < .004. Statistical analysis was conducted using Stata software, version 14.0 (StataCorp). 
Results
Sample Characteristics
Treatment-Related Symptom Burden (Mean Top 5 Symptom Scores)
The mean (SD) of the top 5 most severe symptoms reported by OPC survivors are summarized in Table 1 and included the following symptoms in descending order: 3.9 (2.9) for dry mouth, 2.6 (2.8) for swallowing and chewing, 2.3 (2.4) for mucus, 2.0 (2.5) for fatigue, and 2.0 (2.6) for choking. Overall treatment-related symptom burden among all survivors was low (mean, 2.6; median, 2.0; range, 0-10). Patients with late LCNP reported significantly worse mean treatment-related symptom scores compared with those without LCNP (4.5 for patients with LCNP vs 2.5 for patients without LCNP; mean difference, −2.0; 95% CI, −2.7 to −1.3).
Unadjusted univariate analyses found that survival time, T stage, therapeutic modality, chemotherapy, RT dose, fractionation and modality, and smoking had significant associations with mean scores. Multiple linear regression identified that late LCNP was significantly associated with worse mean top 5 MDASI-HN symptom scores (coefficient, 1.54; 95% CI, 0.82-2.26; adjusted R 2 = 0.08), adjusting for age, survival time, sex, therapeutic modality, T stage, subsite, RT modality, smoking, and normal diet before treatment. 
GFI and Mean Interference
Late LCNP was not significantly associated with worse mean interference scores (coefficient, 0.72; 95% CI, 0.09-1.35) after multivariable adjustment and correction for multiple testing. Association of late LCNP with individual domains of interference scores categorized as activity related (coefficient, 0.90; 95% CI, 0.25-1.54) and psychosocial related (coefficient, 0.56; 95% CI, −0.08 to 1.21) was also not statistically significant after correction for multiple comparison.
Individual Top 5 Symptoms and Voice and Speech Symptoms
Individual symptoms that were most severe among patients with late LCNP, in rank order of means, included difficulty swallowing and chewing (5.5 in patients with LCNP vs 2.5 in patients without LCNP; mean difference, −2.9; 95% CI, −3.9 to −2.0), dry mouth (4.9 in patients with LNCP vs 3.8 in patients without LCNP; mean difference, −1.0; 95% CI, −2.0 to −0. Figure 3 summarizes multivariate adjusted coefficients for late LCNP and MDASI-HN scores. Among patients with LCNP, a higher proportion reported severe (20.0% in patients with LCNP vs 5.8% in patients without LCNP) and moderate (40.0% in patients with LCNP vs 15.6% in patients without LCNP) symptoms. In addition, among patients with LCNP, severe scores (≥7) were reported by 15 of 35 (42.9%) for swallowing and chewing symptoms and 13 of 35 (37.1%) for voice and speech problems. Among 35 patients with late LCNP, 6 patients rated difficulty swallowing, 4 rated voice and speech problems, 4 rated choking, and 3 rated mucus as 10 of 10 severity, the worst possible score on the MDASI-HN (eFigure in the Supplement).
Discussion
This large, cross-sectional survivorship survey yielded a comprehensive, quantitative assessment of the association between late LCNP and cancer treatment-related symptoms and subse- Our results suggest that the mean top 5 MDASI-HN symptom score is 1.54 points worse among survivors with LCNP compared with those without LCNP after adjusting for age, survival time, sex, therapeutic modality, T stage, subsite, RT modality, smoking, and normal diet before treatment. This finding reflects a moderate effect size of LCNP on most prevalent symptoms in this survivor population. The adjusted R 2 of the model suggests that late LCNP explained 8% of the variation in the mean top 5 MDASI-HN symptom scores after accounting for the effects of other covariates. This modest to moderate adjusted R 2 for a single exposure may reflect the variability of nerve paresis associated with symptoms among survivors because of the cross-sectional sampling along the continuum of nerve paresis (partial through complete denervation) because progressive deterioration over time is characteristic of late LCNP. 30 That is, patients with LCNP responded to the survey from 2 to 16 years after treatment, a timeframe during which the clinical course of LCNP was likely to vary. This observation is consistent with previous case reports that suggest that functional status of cases approximated the trajectories of their neuropathies. 7 That is, as late LCNP remained clinically stable, physiologic impairment remained steady, and as late LCNP progressed, coincident severe decline in function and body weight occurred. 7 Treatment of OPC may lead to multiple local symptoms, including dry mouth, dysphagia, mucositis, choking, speech problems, and lack of taste, among others, which can contribute to excessive distress and lower QOL. 27, 31 The mean top 5 Abbreviations: IMRT-SF, split-field intensity-modulated radiation therapy; IMRT-WF, whole-field intensity-modulated radiation therapy; LCNP, lower cranial neuropathy; NA, not applicable; RT, radiotherapy.
a P < .001.
b P < .25 during univariate analysis.
c P < . 05 after multivariate analysis.
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symptoms reported by our study population predominantly featured similar local head and neck-specific adverse effects (4 of 5, except fatigue). Given the central role of these symptoms in daily functioning, it is not surprising that patients with late LCNP also reported higher levels of GFI, which was correlated with symptom severity; however, this association was not statistically significant after multiple comparison correction. Of interest, among individual components of the interference domain, late LCNP was more strongly associated with activity-related interference but not psychosocial-related scores, but this association was also not statistically significant. These findings might suggest a more lasting burden of LCNP on activity as opposed to emotional distress. The association between psychosocial distress and late symptoms may attenuate over time as patients learn to cope with the emotional distress associated with physical impairment. Similarly, a previous study 32 that investigated QOL among patients with oral cancer according to the Functional Assessment of Cancer Therapy-Head and Neck found significantly improved emotional scores in the same time that functional scores decreased between 1 month and 6 months after treatment. The authors attributed this finding to a response shift, which they described as emotional adaptation to decline in physical functioning and improved coping with the new normal level of functioning. 32 These trends are also consistent with results of a study among patients with HNC that used the MD Anderson Dysphagia Inventory (MDADI) and reported better scores for the emotional vs functional component. 33 Overall, late LCNP was most strongly associated with worse swallowing and chewing as well as speech and voice symptoms, with LCNP being associated with 10% of the variation in swallowing and chewing scores and 17% of the variation in speech and voice symptoms scores. These findings agree with those reported by a longitudinal study 6 among 57 OPC survivors, wherein 3 patients with LCNP experienced a severe decline in swallowing function over time according to patient-reported MDADI scores, practitioner-rated radiographic dysphagia grades, and standard diet scales. Late LCNP was also associated with worse mucus and choking scores in the present survey, which may reflect symptoms associated with swallowing effects of LCNP. Inefficient swallows described previously in patients with LCNP affect the ability to clear food and liquids through the oropharynx, including mucus. Mucus accumulation can lead to unpleasant symptoms of gagging and choking, which may also reflect aspiration of food and liquids during swallowing, as previously reported in 100% of cases of neuropathy-mediated, late RT-associated dysphagia largely occurring in long-term OPC survivors at more than 5 years after treatment. 34 Lower cranial nerves are critical to the oropharyngeal phase of swallowing as well as voice and speech production. [5] [6] [7] [8] [9] Cranial nerve IX palsy may lead to swallowing problems by way of loss of function of the stylopharyngeus muscle and loss of pharyngeal sensation, whereas cranial nerve X injury can cause paralysis of the pharyngeal constrictors and/or vocal cords (depending on the branch) and thereby contribute to dysphagia and voice impairment. Neuropathy of cranial nerve XII results in tongue paresis, atrophy, and fibrillations, with implications also for swallowing and speech precision. [5] [6] [7] [8] [9] Therefore, the specific patterns of symptom burden detected in this survey align with the clinical findings of specific LCNPs among patients with OPC. Fatigue is widely prevalent in HNC survivors but was also reported with greater severity among patients with LCNP, possibly because of late LCNP-associated mucus problems that could exacerbate sleep disturbance. 35 In addition, LCNPassociated swallowing dysfunction can contribute to longterm micronutrient deficiency and complications, such as anorexia, malnutrition, anemia, and cachexia. Cachexia especially has been linked in a past study 36 to functional limitations and fatigue. Furthermore, lack of association between late LCNP and dry mouth is expected given that dry mouth is not a consequence of lower cranial nerve injury and is instead caused by RT-induced hypofunction of salivary glands. 37 Symptom burden can be reflected by many measures of the MDASI-HN. Each of the MDASI-HN outcomes that we reported in this analysis is described in the MDASI user guide as an option to report findings from the instrument. It is important to acknowledge, however, that the mean top 5 MDASI-HN metric has not been evaluated for validity in a dedicated publication. The metric is, however, supported by both the MDASI user manual and the expected performance relative to clinical and demographic classifiers in this report and other publications. [23] [24] [25] [26] Evaluation of individual items as a secondary end point also suggests that late LCNP had the greatest negative association with difficulty swallowing, speech, mucus problems, choking, and fatigue symptoms among OPC survivors. For this reason, the functional translation of late LCNP may lead to placement of feeding tubes, tracheostomy tubes, aspiration, and pneumonia, as has been described in smaller series with more objective metrics. [6] [7] [8] Smaller series, however, failed to include non-LCNP controls such that effect sizes from these more objective metrics are not available in the current literature. It is our hope that these survey-based quantifications offer initial progress toward quantifying the burden of this rare but devastating late consequence of treatment. This research can inform development of supportive care interventions among OPC survivors to target these symptom domains through personalized speech and swallowing therapy and nutritional consultations, and such implications need to be assessed in future studies. Given the high degree of symptom burden, integration of interdisciplinary supportive care should be given early to potentially attenuate or slow the functional burden of LCNP. Diverse symptoms likely merit involvement of speech pathologists, oral oncologists, physiatrists, physical therapists, nutritionists, and oncology nurses, among others, to optimize outcomes. Targeted and individualized treatments must take into consideration patient perspectives, and routine symptom screening using validated patient-reported outcomes, such as the MDASI-HN, in patients with LCNP may also be of value to prioritize areas for intervention.
Limitations
With 889 OPC survivors, this study is the first, to our knowledge, to quantitatively estimate the association between late LCNP and cancer treatment-related severity of symptoms. There are, however, limitations to acknowledge. Cross-sectional survey administration led to respondents with varying survival time and survival bias. Given the long latency period for late LCNP development, risk is highest among responders with greater survival time. For this reason, survival time was accounted for in all regression models. The small number of events is a limitation inherent to studies of LCNP because it is known to be a rare late occurrence. Nonetheless, consistently robust estimates on study outcomes were identified that reflect expected outcomes from clinical observations. This study was conducted in a tertiary care cancer center, making it subject to referral bias that can limit generalizability of results to other hospitals and communities, but sample characteristics are common of modern OPC in the United States; therefore, this issue is expected to be negligible. The largest threat to validity is the possibility of misclassification. Late LCNP ascertainment may be incomplete because of loss to followup, missing medical record details, or differential follow-up among patients with mild cranial neuropathy symptoms insufficient to merit return to the clinic for late LCNP. Therefore, exposure misclassification in this study would most likely lead to underreporting of LCNP and consequently to underestimation of the association of LCNP with symptom burden. Thus, if misclassification was substantial, actual coefficients for LCNP and symptom burden may be higher than reported in this study. Because this was a cross-sectional survey, the degree or time course of LCNP was not standard in all cases. There was, for instance, no standard method to document degree of neuropathy in medical records. Likewise, the association between LCNP and diet and other functional variables was not assessed and will be investigated in future publications. We also did not obtain detailed, validated measures of anxiety and depression; therefore, the association of late LCNP with these domains needs to be investigated in future studies using other, more robust measures.
Conclusions
In this large survey study, patients with late LCNP reported significantly worse cancer treatment-related symptoms and worse symptoms associated with motor functions of the upper aerodigestive tract (swallowing, voice), revealing the relevance of late LCNP to both symptom severity and QOL. Among patients with LCNP, a higher proportion reported severe and moderate symptoms. The study findings suggest the need for long-term surveillance of late LCNP among patients with HNC and OPC, particularly in light of epidemiologic trends that suggest increasing numbers of OPC survivors at risk of late symptoms in the immediate years ahead. 6 
